Paolo Tarantino (@ptarantinomd) 's Twitter Profile
Paolo Tarantino

@ptarantinomd

MD, PhD, Medical Oncologist | Clinical Fellow @DanaFarber | @Harvard. SoMe Editor @ESMO_Open. Interested in breast oncology, HER2, ADCs and good music.

ID: 958742483856486400

calendar_today31-01-2018 16:43:15

13,13K Tweet

26,26K Takipçi

651 Takip Edilen

Paolo Tarantino (@ptarantinomd) 's Twitter Profile Photo
Paolo Tarantino
@ptarantinomd

a year ago

A-BRAVE phase 3: among pts with TNBC and (mostly) RD after NACT, adjuvant avelumab for 1 year did not sign improve DFS (68.3% vs 63.2%, p=0.1) but did improve DDFS and OS (84.8% vs 76.3%, p=0.02), with low rate of AE. Impressive academic effort with extremely interesting results.

A-BRAVE phase 3: among pts with TNBC and (mostly) RD after NACT, adjuvant avelumab for 1 year did not sign improve DFS (68.3% vs 63.2%, p=0.1) but did improve DDFS and OS (84.8% vs 76.3%, p=0.02), with low rate of AE. Impressive academic effort with extremely interesting results.